CS014

CS014 is a novel small molecule histone deacetylase (HDAC) inhibitor with multimodal epigenetic effects. It is being developed primarily for the treatment of idiopathic pulmonary fibrosis (IPF), a rare and progressive lung disease characterized by fibrosis and vascular remodeling. Preclinical studies have demonstrated that CS014 can reverse fibrosis, prevent pathological vascular remodeling associated with pulmonary hypertension, and regulate platelet activity, local fibrinolysis, and clot stability—potentially preventing thrombosis without increasing bleeding risk. These properties suggest disease-modifying potential in IPF as well as possible utility in rare cardiovascular diseases. The drug was originally acquired from Emeriti Bio by Cereno Scientific in 2019 and is being developed collaboratively by Cereno Scientific, Emeriti Bio, and the University of Michigan. A first-in-human Phase I clinical trial began in June 2024 to assess safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in healthy volunteers[1][2][5][6].